anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Serious including fatal hemorrhagic events can occur with LENVIMA. Across SELECT (DTC), Study 205 (RCC) and REFLECT (HCC), hemorrhagic events of any grade occurred in 29% of the 799 patients treated with LENVIMA as a single agent or in combination with everolimus. The most frequently reported hemorrhagic events (all grades and occurring in at least 5% of patients) were epistaxis and hematuria. 

In SELECT, Grade 3 to 5 hemorrhage occurred in 2% of patients receiving LENVIMA, including 1 fatal intracranial hemorrhage among 16 patients who received LENVIMA and had CNS metastases at baseline. In Study 205, Grade 3 to 5 hemorrhage occurred in 8% of patients receiving LENVIMA with everolimus, including 1 fatal cerebral hemorrhage. In REFLECT, Grade 3 to 5 hemorrhage occurred in 5% of patients receiving LENVIMA, including 7 fatal hemorrhagic events [see Adverse Reactions (6.1)].

Serious tumor related bleeds, including fatal hemorrhagic events, occurred in patients treated with LENVIMA in clinical trials and in the post-marketing setting. In post-marketing surveillance, serious and fatal carotid artery hemorrhages were seen more frequently in patients with anaplastic thyroid carcinoma (ATC) than in other tumor types. The safety and effectiveness of LENVIMA in patients with ATC have not been demonstrated in clinical trials.

Consider the risk of severe or fatal hemorrhage associated with tumor invasion or infiltration of major blood vessels (e.g. carotid artery). Withhold and resume at reduced dose upon recovery or permanently discontinue LENVIMA based on the severity [see Dosage and Administration (2.7)].
The present invention relates to a method for manufacturing a dye comprising: a first agent; and a second agent, wherein the first and second agents are mixed 1 : 1 ratio. The first agent is prepared by mixing, at a particular ratio, a first mixture and a second mixture at a certain ratio. The first mixture is prepared by mixing purified water, commonly used p-phenylenediamine, n-phenyl-p-phenyldiamine, sulfuric acid-4-ethoxy-m-phenyldiamine, m-aminophenol, resorcin, a solubilizer, an antioxidant, an antistatic agent, a humectant, a hair protecting agent, a hair penetrating agent, an emulsifying agent, a surfactant, a pH-adjusting agent, fragrance, a skin-protecting agent, and the upper water of earth-mixing water, stirring the same at high temperature of 80 to 90 ℃, and then cooling the same at 25 to 35 ℃. The second mixture is prepared by mixing the upper water from earth-mixing water, organic germanium, a cistanche extract, an Ecklonia cava extract, and camellia oil. The second agent is prepared by mixing a first mixture and a second mixture. The first mixture is prepared by mixing, at a particular ratio, purified water, hydrogen peroxide, a hair protecting agent, an emulsifier, a surfactant, and a pH adjusting agent, and a skin protecting agent, stirring the same at a high temperature of 80 to 90 ℃, and cooling the same at 25 to 35 ℃. The second mixture is prepared by mixing the upper water of earth-mixing water, a cistanche extract, an Ecklonia cava extract, and camellia oil.
Dexamethasone Tablets USP are available for oral administration containing 4 mg of dexamethasone USP. Each tablet contains the following inactive ingredients: croscarmellose sodium, ferric-ferrous oxide (4 mg only), ferric oxide red (1.5 mg and 6 mg only), ferric oxide yellow (0.5 mg, 1 mg, 4 mg and 6 mg only), magnesium stearate, microcrystalline cellulose, and lactose monohydrate.

Dexamethasone, a synthetic adrenocortical steroid, is a white or almost white, crystalline powder. It is practically insoluble in water, sparingly soluble in anhydrous ethanol, slightly soluble in methylene chloride. The molecular formula is C22H29FO5. The molecular weight is 392.46 g/mol. It is designated chemically as 9-fluoro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione and the structural formula is:

FDA approved dissolution test method differs from the USP dissolution test methods.
Thirty patients in this group will receive infusion of 100 saline solution. After 15 min of beginning of this infusion they will start receiving general anesthesia administration.
This is a randomized, double-blind, placebo-controlled trial of testosterone replacement in older men with age-associated hypogonadism and subsyndromal depression. Men will receive either 7.5 gm/qd of testosterone gel or a placebo gel for 12 weeks. The double-blind phase will be followed by a 12 week open-label extension in which all subjects will receive 7.5 gm/qd of testosterone gel.

Procedures: Depressive symptoms will be assessed with the Hamilton Depression Rating Scale (HDRS) and the SCL-20, a 20-item self-report depression scale that has been shown to have high reliability and validity and to be sensitive to changes in depressive symptoms in outpatients in primary care settings. The short form (16 item) Endicott Quality of Life Enjoyment and Satisfaction Scale will be used to assess quality of life changes. The Medical Outcomes Study Short-Form 36 (SF-36) will be used to assess changes in functional status. Demographic information, medical history and current medications will be determined at baseline and follow up, via patient interview and chart review. Overall medical morbidity will be ascertained with the Cumulative Illness Rating Scale. All outcome measures (SCL-20, Endicott Quality of Life Scale, HDRS,SF-36) will be assessed at baseline, week 12 (end of the double-blind phase)and week 24 (end of the extension phase). Blood draws will be done at baseline, week 12 and week 24. Laboratory assays for testosterone leves at baseline, week 12 and week 24 will be performed at the same time to minimize interassay variability.
The present invention relates to a medicine having the functions of promoting qi circulation to relieve pain and activating blood circulation to dissipate blood stasis for curing ischemia diseases of urgent and chronic cardiac muscles. The present invention is prepared from radix notoginseng extract, rhizoma ligustici chuanxiong, lignum dalbergiae odoriferae and valerian and has the advantages of outstanding curative effects and fast effects. By the checking certification of statistics, the medicine of the present invention can take effects within 2 to 3 minutes. The present invention has obvious protective actions for the damage of cardiac muscles caused by re-pouring blood, and the range of infarction is reduced by 30%. Within the dose range of experiment, the present invention protects cardiac muscles and has no obvious dose dependence. A product is obviously superior to similar products on the aspects of decreasing the frequency of angina pectoris attack, shortening the time of angina pectoris attack, etc. and under the conditions of improving the blood supply of the cardiac muscles and rehabilitating ischemic cardiac muscles. The pharmaceutical formulation of the present invention has the advantages of scientific preparation technology, high stability, few administration doses, high safety and no toxic side effects.
Methods and systems are disclosed for determining patient compliance for using a compression therapy device. The systems may include a compression therapy sleeve and a controller having a non-transitory memory device. During a therapy session, the controller may record in the memory device operational therapy data obtained from sensors associated with the controller and/or sleeve. The controller may calculate a compliance metric based in part on the therapy data. The controller may then communicate the data or metric to one or more recipients. The methods may include allowing the patient to transfer a removable memory device from the controller to a personal computer, and uploading the therapy data or metric stored on it to a recipient website. Alternative methods may include the patient receiving the metric from the controller at the end of the therapy session, and then providing the metric to a recipient by phone.
Screening and Cognitive Behavioral Therapy. The intervention group will be screened and if they need criteria they will complete the 6, 30-minute online, interactive CBT modules over 6 weeks.
FIELD: medicine.SUBSTANCE: invention refers to medicine, cardiology, gerontology. Age is determined in the patients, collect data of anamnesis on the presence of atrial fibrillation (AF), arterial hypertension, diabetes mellitus, ischemic heart disease – acute myocardial infarction, peripheral arterial atherosclerosis, congestive chronic cardiac failure (CCF), thromboembolic complications (TEC), including cerebral strokes. Diagnosing the presence of AF by analyzing the recorded electrocardiogram (ECG) or the Holter ECG monitoring results, the presence of atherosclerotic plaques by duplex scanning of the arteries; reduction of ejection fraction (EF) in patients with CCF symptoms accompanying echocardiography. Prescription/non-prescription of oral anticoagulants (OAC) is assessed. Using the questionnaire, the patient's adherence to the recommended OAC intake is determined. According to the declared mathematical formula additional risk index of TEC (TEC ARI) is calculated. Value ARI TEC shows the low risk – if the value is up to 0.2, the average risk is 0.3–0.6, the high risk is 0.7–0.9 and the ARI TEC is more than 1.0 – a very high additional risk of TEC.EFFECT: method provides a universal and accurate assessment of the additional risk of TEC in elderly patients suffering AF, by determining the total risk of TEC, evaluating the conducted anticoagulant therapy, as well as diagnosing adherence of the patients to the recommended treatment.1 cl, 1 tbl, 4 ex
PURPOSE: Total knee arthroplasty is the main method for the treatment of advanced haemophilic knee arthritis. Due to the particularity of hemophilia, the blood management plan is the focus of the perioperative period for haemophilia patients. This study aimed to investigate the clinical effect and safety of intra-articular injection of tranexamic acid in patients with haemophilia.
METHODS: This is a retrospective study. According to whether tranexamic acid is used or not, patients are divided into tranexamic acid group (n=30) and non-tranexamic acid group (n=29). Total blood loss, intraoperative blood loss, complete blood count, total amount of coagulation factor VIII (FVIII) usage, coagulation biomarkers, inflammatory biomarkers, knee range of motion, knee joint function, pain status, complication rate, and patient satisfaction were assessed and compared at a mean follow-up of 16 months.
RESULTS: Injecting tranexamic acid into the knee joint cavity can effectively reduce the hidden blood loss and total blood loss (P<0.001), and reduce the patient's early postoperative inflammation biomarkers, pain status, and limb swelling. Therefore, the patient can obtain a better range of motion following total knee arthroplasty. In the long run, in terms of joint function and surgical satisfaction, there are no statistically significant differences. In addition, there are no statistically significant differences between the two groups of patients in terms of the total amount of FVIII usage, length of stay, and hospitalization expenses.
CONCLUSION: In patients with haemophilia, intra-articular injection of tranexamic acid during total knee arthroplasty can effectively reduce postoperative blood loss, early postoperative inflammation levels, pain and limb swelling, and enable patients to receive higher-quality rehabilitation exercises to get better joint function. Previous studies on TKA in haemophilic patients have already demonstrated the efficacy of intra-articular injections of TXA in reducing postoperative blood loss. Our study confirms this efficacy.
Bronchial remodelling is a prominent feature of severe asthma and a potential therapeutic target. Some data indicate that Th17 cytokines in particular IL-22 may be involved in remodelling processes in vitro, and in skin remodelling in vivo. The aim of the inventors was to evaluate if Th17 cytokines are involved in bronchial remodelling in a severe model of allergic asthma, and if this was amplified by co-sensitization with NOD2 agonist, MDP, a ligand favouring Th17 polarization. Dog allergen challenge led to a predominant neutrophilic infiltration in Broncho-alveolar lavage (BAL), increased dog-specific IgE production, airways hyperresponsiveness, and increased Thl7 cytokine production. Increased bronchial remodeling was observed in dog allergen challenged mice compared to control. IL-22 deficiency decreased airway hyperresponsiveness, bronchial mucus production as well as peribronchial collagen deposition, in the allergen-challenged group. Th17 cytokines in particular IL-22 participate in the bronchial remodeling in a chronic model of neutrophilic asthma, and may represent a therapeutic target in severe asthma.
279,445. I. G. Farbenindustrie Akt.- Ges. Oct. 20, 1926, [Convention date]. Medicines for internal use. - Hormones, influencing the action of the heart, which are soluble in water but not in strong alcohol, are obtained from the hearts of warm-blooded animals by extraction with water or with aqueous organic solvents, ballast substances such as albumens and lipoids being removed from the extracts by known methods. According to an example, comminuted hearts are extracted with water, the solution is concentrated if necessary, impurities are removed by adding alcohol up to 60 per cent strength and by cooling, the filtrate is desiccated, lipoids are dissolved out by high strength alcohol, and the hormone remaining is dissolved in water and sterilized by heating or by adding an antiseptic. Reference is made to a known alcohol-soluble heart hormone obtained from the hearts of coldblooded animals, to an alcohol-soluble substance obtained by extracting heart tissue with Locke's solution according to Specification 250,230 (as open to inspection under Sect. 91 of the Acts), and to Specifications 306,606 and 306,608. The Specification as open to inspection under Sect. 91 (3) (a) contains also the subject-matter of Specifications 306,606 and 306,608 and states that lipoids removed from an aqueous solution of heart hormone by treatment with a solvent such as methylene chloride may be freed from solvent by evaporation and from phosphatides by treatment with acetone. This subject-matter does not appear in the Specification as accepted.
The invention relates to vaccines and means for vaccination of a host with the intention of preventing or controlling specific T-cell mediated pathologies. The vaccine is made of antiidiotype antibodies which are internal reflections of a segment of the T-cell receptor (TCR), found on the surface of the pathogenic T-cells. The vaccine is applied on the host in a manner which includes an immune reply, directed against the TCR of the pathogenic cells. This immune response regulates or eliminates the pathogenic T-cells, and in this way eliminates the pathogenesis. The invention relates to a mean for the determination of a suitable amino acid sequence of such a vaccine. 17 claims
The invention features an apparatus for producing a fluid stream having plurality of nanoparticles in the fluid stream. The apparatus includes a source configured to provide a fluid stream having a first randomly sized distribution of a plurality of nanoparticles; a flow control zone configured to receive the fluid stream from the source and to control the fluid stream to produce a controlled fluid stream having a selected flow rate; a separation zone configured to receive and to separate the selectively controlled fluid stream into at least one separated fluid stream having a non-randomly sized distribution of nanoparticles; and a collection zone capable of receiving the separated fluid stream according to at least one non-random sized distribution of nanoparticles to produce at least one collected stream. The apparatus is configured for a continuous flow of the fluid stream. A size of a nanoparticle can be related to an intrinsic core diameter, a hydrodynamic diameter, and a combination of intrinsic core diameter and hydrodynamic diameter measurements. The nanoparticles can include non-magnetic nanoparticles, partially magnetic nanoparticles, magnetic nanoparticles, superparamagnetic nanoparticles, and a combination of at least two different nanoparticle types. The invention also features methods for producing said fluid streams. The invention further features apparatus and methods for cancer confirmation and targeted therapeutic drug development.
In recent years, the prevalence of smartphone addiction has significantly increased. This situation has raised concerns about its potential impact on health aspects, such as sleep quality and mental health, particularly among vulnerable populations like pregnant women. This study aimed to identify the factors that determine sleep quality in pregnant women and examine the relationship between smartphone addiction, depression, and sleep quality. This descriptive correlational study included 257 pregnant women in their second and third trimesters who were registered at six family health centers between September 2022 and March 2023. Data were collected using a sociodemographic questionnaire, the Smartphone Addiction Scale Short Form, Edinburgh Postnatal Depression Scale, and Pittsburgh Sleep Quality Index. Regression and mediation analyses were performed for the data. Of the participants, 44.4 percent had poor sleep quality. Depression and third trimester were significant determinants of sleep quality. The bootstrapping results revealed that smartphone addiction led to an increase in the level of depression (β = 0.145; p < .001). Depression worsened sleep quality (β = 0.262; p < .001). The smartphone addiction did not significantly affect sleep quality (β = 0.020; p = .279). Depression mediates the relationship between sleep quality and smartphone addiction (β = 0.038; 95 percent CI [0.018: 0.062]). The study highlights that while smartphone addiction does not directly impact sleep quality in pregnant women, it is associated with increased depression levels, which subsequently worsen sleep quality. It is recommended that healthcare providers monitor smartphone usage and mental health in pregnant women to mitigate the risk of sleep disturbances and improve overall well-being.
Objectives: To evaluate physicians' opinions concerning continuous deep sedation until death (CDSUD) and implementation of Claeys-Leonetti; a law intended to be applicable to all patients, but without a specific framework for children thus giving rise to ethically and legally complex situations. The secondary objective was to identify if physicians' characteristics could influence their opinions. Study Design: This was a national, multicenter, noninterventional cross-sectional survey from January 30, 2020, until March 1, 2020. The target population consisted of French physicians involved in children's end-of-life situations. The validated questionnaire explored respondents' characteristics and their opinions on four hypothetical pediatric clinical cases. Results: Analysis was conducted on 391 respondents. The oncological situation was more easily recognized as end of life compared with the neurological pathology (77% vs. 40.4%). Dependence on mechanical ventilation was another major factor influencing physicians in identifying end-of-life situations. Physicians clearly recognized the difference in intention between CDSUD and euthanasia. They accepted to implement CDSUD more easily in newborns. The withdrawal of artificial nutrition and hydration gave rise to divergent opinions. Respondents were in favor of adolescents' decision-making autonomy and their access to drafting advance directives. The child's best interest prevailed in case of objection by parents, except in situations outside the law's framework or in cases of disagreement within the health care team. Conclusion: Results of our study showed differences in the interpretation of the law concerning the CDSUD application framework and provide elements for reflection, which may ultimately contribute to the development of specific guidelines in CDSUD in children at the end of life.
The present invention relates to the technical field of a functional beverage. The multifunctional beverage for resisting virus infection contains an edible sweetening agent frequently used by a common beverage, an edible sour agent and water. The present invention is characterized in that the beverage contains 0.01m% to 1m% of food grade sialic acid or sialic acid derivatives, 0.2 to 6m% of protein with bioactivity, a polypeptide mixture, ginseng, ginger, salvia, mushroom, astragalus root, honeysuckle flower, garlic, american ginseng or an extractive of tea. The extractive and swift's nest acid have synergistic action, and genetic substances of a cold virus and other viruses can be effectively prevented from entering host cells and being duplicated. The beverage can perform the action of preventing cold by drinking for a long time, enhance the absorption capacity of an intestinal tract for vitamin and mineral substances and enhance the learning capacity of a brain. The functional beverage is helpful for enhancing physical quality and intelligence development level.
X-RAY CONTRAST MATERIALS FOR THE GASTROINTESTINAL TRACT                ABSTRACT OF THE DISCLOSURE         Hydroxyalkyl amino-substituted triiodoben-zoates are provided, where the remaining position is substituted by amino or carboxy.  The compounds have low solubility in the gastrointestinal tract, but are resorbable from extravisceral body cavities.  They can be readily formulated and used as contract media for the plain radiography of the GI tract.          Also, addition polymers comprised of triiodo compounds bonded through an amino nitrogen to a non-oxo-carbonyl group of an addition polymerizable monomer are provided.  The polymers are highly water soluble physiologically acceptable, and not resorbable from the GI tract, but from the extravisceral body cavities.  The polymers find use for computer tomography of the GI tract.   20219945               35.
<P>PROBLEM TO BE SOLVED: To provide a skin care preparation for external use having excellent moisturizing action and roughened skin ameliorating effect.  <P>SOLUTION: This preparation having excellent moisturizing action and roughened skin ameliorating effect is produced by compounding a skin care preparation for external use with a component derived from a plant of the family Empetraceae. The plant of the family Empetraceae is e.g. a plant belonging to the genus Empetrum such as Empetrum nigrum Linn.var. japonicum K. Koch, Empetrum rubrum and Empetrum nigrum Linn, a plant of the genus Ceratiola such as Ceratiola ericoides.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
PROBLEM TO BE SOLVED: To obtain the subject new compound, comprising a specific silicon compound containing a quinone or an azo type chromophore, capable of manifesting an excellent nontoxic level without using an oxidizing agent and useful as a dyeing composition, etc., for human keratinous fiber such as hair. SOLUTION: This new silicone compound is represented by formula I [R is a 1-10C alkyl, phenyl or 3,3,3-trifluoropropyl and at least 80% of groups R are methyl; B is R or A  A is a chromophore such as a quinone represented by formula II [R4 is a 1-6C alkyl, OH, a 1-4C alkoxy, etc.; (m) is 0-2; D is SO2 NH, CONH, O, etc., W is an alkylene, etc.; (n) is 2, etc.] or an azo type represented by formula III}, (r) is 0-50; (s) is 0-20], formula IV [(t) is 0-10; (u) is 1-6; (t+u) is >=3] and formula V and is useful as a direct dye, etc., for dyeing human keratinous fiber. The compound is obtained by carrying out the hydrosilylating reaction of a compound in which the group A is H with an unsaturated compound having the quinone or azo type chromophore.